Cleaved-C1R (R463) Antibody

What is the Cleaved-C1r HC (R463) Antibody and what specific epitope does it recognize?

The Cleaved-C1r HC (R463) Antibody specifically detects endogenous levels of the fragment of activated C1r heavy chain protein resulting from proteolytic cleavage adjacent to arginine 463. C1r is a serine protease that functions as a critical component of the classical complement pathway. This antibody recognizes the neo-epitope created by the cleavage event, derived from the amino acid range 414-463 of human C1R . This specificity makes it valuable for studying complement activation dynamics without detecting the intact, unactivated C1r protein.

Which applications have been validated for the Cleaved-C1r HC (R463) Antibody?

The Cleaved-C1r HC (R463) Antibody has been validated primarily for Western Blot (WB) and ELISA applications . For Western Blotting, the recommended dilution range is 1:500-1:2000, while for ELISA applications, a dilution of 1:10000 is recommended . The antibody typically detects a band of approximately 51kDa in Western blot analysis, corresponding to the cleaved C1r heavy chain fragment .

What species reactivity has been confirmed for this antibody?

The Cleaved-C1r HC (R463) Antibody has confirmed reactivity with human, rat, and mouse samples . This cross-species reactivity makes it valuable for comparative studies and translational research using rodent models of complement-related diseases with human relevance. The conservation of the epitope across these species suggests a functionally important region in the C1r protein.

What are the optimal storage conditions for maintaining antibody activity?

For optimal stability and activity retention, the Cleaved-C1r HC (R463) Antibody should be stored at -20°C for up to one year from receipt . The antibody is typically supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide as a preservative . Repeated freeze-thaw cycles should be avoided to maintain antibody efficacy and specificity. Some manufacturers also suggest storage at -80°C as an alternative for longer-term storage .

What are the specific formulation components that ensure antibody stability?

The antibody is formulated in a liquid buffer containing:

• PBS (phosphate-buffered saline) as the base buffer

• 50% glycerol to prevent freezing damage and maintain stability

• 0.5% BSA (bovine serum albumin) to reduce non-specific binding and increase stability

• 0.02% sodium azide as a preservative to prevent microbial growth

This formulation is designed to maintain antibody integrity during storage and handling, while minimizing potential interference with downstream applications.

How can researchers validate the specificity of Cleaved-C1r HC (R463) Antibody in their experimental system?

A robust validation protocol for the Cleaved-C1r HC (R463) Antibody includes:

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide (C1r HC cleaved at R463) before application to Western blot or ELISA. A significant reduction in signal confirms specificity, as demonstrated in published validation studies .

• Positive and negative controls:

  • Positive: Samples with known complement activation (e.g., serum activated with immune complexes)

  • Negative: Samples from C1r-deficient models or CRISPR knockout cell lines

• Activation-dependent detection: Compare samples with and without complement activation triggers to confirm signal increases correlate with activation status.

• Molecular weight verification: Confirm detection of the expected 51kDa fragment in Western blot applications .

• Correlative approaches: Compare results with alternative methods of detecting complement activation (C3 cleavage products, C4d deposition).

What are the optimal experimental conditions for detecting cleaved C1r in complex biological samples?

For optimal detection of cleaved C1r in complex biological samples such as tissue lysates, serum, or plasma:

Sample Preparation:

• Include protease inhibitors (except serine protease inhibitors that might inhibit complement activation) during sample collection

• Process samples rapidly at 4°C to minimize ex vivo activation

• Consider gentle lysis buffers (e.g., NP-40 or RIPA) for cellular samples

Western Blot Protocol:

• Use 10-12% SDS-PAGE gels for optimal resolution around 51kDa

• Transfer conditions: 100V for 60-90 minutes for efficient transfer of proteins

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary antibody: 1:500-1:2000 dilution, overnight incubation at 4°C

• Secondary antibody: HRP-conjugated anti-rabbit or anti-mouse (depending on primary antibody source) at 1:5000-1:10000

• Detection: ECL substrate optimized for medium abundance proteins

ELISA Protocol:

• Coating buffer: Carbonate/bicarbonate buffer (pH 9.6)

• Coating concentration: 1-10 μg/ml of capture antibody

• Primary antibody dilution: 1:10000

• Sample dilution series: Consider testing a range (1:2 to 1:100) to establish optimal working dilution

How can researchers employ this antibody to investigate complement activation in disease models?

The Cleaved-C1r HC (R463) Antibody serves as a powerful tool for investigating complement activation in disease models through several methodological approaches:

• Temporal profiling of activation dynamics:

  • Collect samples at multiple timepoints during disease progression

  • Quantify cleaved C1r levels by Western blot densitometry or quantitative ELISA

  • Correlate activation timing with disease manifestations

• Tissue-specific activation mapping:

  • Process multiple tissues from the same experimental subjects

  • Compare cleaved C1r levels across tissues to identify primary sites of complement activation

  • This is especially relevant for autoimmune diseases like SLE, where complement activity varies across tissues

• Therapeutic intervention assessment:

  • Monitor cleaved C1r levels before and after treatment with complement inhibitors

  • Use as a pharmacodynamic biomarker for complement-targeting drugs

  • Establish dose-response relationships between interventions and complement activation

• Genetic model analysis:

  • Compare activation patterns in wild-type versus genetically modified models with complement pathway alterations

  • Important for understanding how C1r deficiency affects susceptibility to infections and autoimmune diseases

What considerations are important when comparing monoclonal versus polyclonal versions of the Cleaved-C1r HC (R463) Antibody?

The choice between monoclonal and polyclonal Cleaved-C1r HC (R463) antibodies depends on experimental requirements:

For critical research requiring absolute confidence in results, using both antibody types in parallel can provide complementary validation.

How can Cleaved-C1r HC (R463) Antibody be utilized to study the relationship between complement activation and autoimmune diseases?

The Cleaved-C1r HC (R463) Antibody provides valuable insights into complement's role in autoimmune pathology:

• Biomarker development:

  • Quantify cleaved C1r levels in patient samples (serum, plasma, synovial fluid)

  • Correlate with disease activity metrics and clinical outcomes

  • Develop prognostic algorithms incorporating complement activation status

• Mechanistic investigations:

  • Track the temporal relationship between complement activation and tissue damage

  • Determine whether complement activation precedes or follows other inflammatory events

  • This is particularly relevant for SLE, where C1r deficiency has been linked to disease susceptibility

• Targeted therapy development:

  • Identify patient subsets with heightened complement activation

  • Monitor therapeutic responses to complement-targeting interventions

  • Define optimal timing for anti-complement therapies based on activation profiles

• Genetic correlation studies:

  • Compare complement activation patterns in patients with different complement gene variants

  • Investigate how polymorphisms in C1R affect cleavage patterns and disease manifestations

  • Build integrated models of genetic susceptibility and environmental triggers

What technical challenges might researchers encounter when using this antibody in tissues with high inflammatory activity?

When using Cleaved-C1r HC (R463) Antibody in highly inflamed tissues, researchers should address several technical challenges:

• Non-specific binding:

  • Inflammatory tissues contain elevated levels of immunoglobulins and sticky matrix proteins

  • Increase blocking agent concentration (5-10% BSA or normal serum from the secondary antibody species)

  • Include 0.1-0.3% Triton X-100 in wash buffers to reduce non-specific interactions

• Epitope masking:

  • Inflammatory mediators can modify proteins or create protein-protein interactions that obscure epitopes

  • Consider using antigen retrieval methods (citrate buffer, pH 6.0) for fixed tissues

  • Test alternative sample preparation methods if initial results are negative despite expected positivity

• Background reduction strategies:

  • Employ longer and more frequent washing steps

  • Use secondary antibodies pre-adsorbed against species present in the sample

  • Consider signal amplification methods for specific signal enhancement

• Validation in inflammatory context:

  • Include tissues from complement-deficient animals exposed to the same inflammatory stimulus

  • Perform peptide competition controls specifically in inflamed tissues

  • Compare results with alternative complement activation markers

What experimental approaches can determine whether the cleaved C1r fragment detected by this antibody is functionally active?

To determine whether the cleaved C1r fragment detected by the antibody represents functionally active protease:

• Enzymatic activity assays:

  • Implement parallel C1r-specific peptide substrate cleavage assays

  • Measure the selective cleavage of Lys/Arg-Ile bonds in complement subcomponent C1s

  • Correlate enzymatic activity with antibody signal intensity

• Downstream activation assessment:

  • Monitor C1s activation status in the same samples

  • Investigate correlation between cleaved C1r levels and C4/C2 cleavage products

  • Establish activation sequence through careful time-course studies

• Inhibitor studies:

  • Apply specific C1r inhibitors to experimental systems

  • Assess how inhibition affects both enzymatic activity and detection by the antibody

  • Distinguish between functionally active fragments and inactive degradation products

• Structure-function analysis:

  • Combine with antibodies targeting other domains of C1r

  • Map the relationship between proteolytic processing and functional activity

  • Consider how the cleavage at R463 relates to the serine protease domain activity described in the literature

How can Cleaved-C1r HC (R463) Antibody contribute to developing blood-based biomarkers for inflammasome activation?

The Cleaved-C1r HC (R463) Antibody can facilitate development of complement-based biomarkers for inflammatory conditions:

• Multiplex biomarker panels:

  • Integrate cleaved C1r detection with other inflammatory markers

  • Combine with markers of inflammasome activation, as suggested by recent research on caspase cleavage motif antibodies

  • Develop ratio-based metrics comparing different activation pathways

• Longitudinal monitoring protocols:

  • Establish baseline levels in healthy individuals

  • Track changes during disease progression and treatment

  • Determine kinetics of complement activation versus resolution

• Technical implementation strategies:

  • Develop capture ELISA systems optimized for clinical samples

  • Validate reproducibility across multiple testing sites

  • Establish reference ranges for different patient populations

• Complementary biomarker approaches:

  • Correlate cleaved C1r with established biomarkers like C-reactive protein

  • Assess whether cleaved C1r provides unique prognostic information

  • Investigate value for early detection of complement activation before clinical manifestations

This approach aligns with growing evidence of biological cross-talk between apoptotic and inflammatory caspases , providing opportunities to develop integrated biomarker systems for inflammatory conditions.